A ccr5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure

HIGHLIGHTS

• who: Yasuhiro Ishihara from the for Life, Hiroshima University, ‑7‑1, Hiroshima, ‑8521, Japan have published the Article: A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure, in the Journal: (JOURNAL)
• what: The aim of this study was to examine the effects of VPA on microglia to identify a target for treating post-developmental behavioral disorders, focusing on neuron- microglia interactions during development. CCL3 mRNA levels showed significant increases in the hippocampi of VPA-treated mice compared with those of vehicle-treated mice (Fig 5); thus, the authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.